( CAMBRIDGE Mass.--(BUSINESS WIRE)--Apr ...)Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting,Health

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 11, 2007 - Gloucester Pharmaceuticals, Inc., an oncology focused biopharmaceutical company, announced today that several abstracts covering preclinical work with romidepsin will be presented at the 2007 Annual Meeting of the American Association of Cancer Research taking place in Los Angeles, CA April 14-18, 2007. These presentations will focus on a variety of preclinical research performed by multiple academic collaborators of the Company. Full text of the abstracts can be viewed on the American Association of Cancer Research website at www.aacr.org.

The presentation schedule of selected abstracts is as follows:

Abstract #689 "Oncogenic H-ras facilitates apoptosis induced by histone deacetylase inhibitors in human urinary bladder cancer cells" will be presented in a poster session Sunday, April 15 from 8:00 am - 12:00 pm. Dr. Shambhunath Choudhary et al of the University of Tennessee are authors.

Abstract #1835 "The HDAC inhibitors romidepsin and PXD101 interact synergistically with Bortezomib in human chronic lymphomocytic leukemia (CLL) cells in association with NF-kB inactivation" will be presented in a poster session on Monday, April 16 from 8:00 am - 12:00 pm. Dr. Yun Dai et al of the Virginia Commonwealth University and Massey Cancer Center are authors.

Abstract #2484 "Histone deacetylase inhibitor FK228 enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines" will be presented in an oral session on Monday April 16 from 11:55 am - 12:10 pm. Dr. Wei Zhang et al of the UT Southwestern Medical Center are authors.

Abstract #3524 "Translational studies of depsipeptide (romidepsin, FK228) a histone deacetylase (HDAC) inhibitor, in patients with head and neck cancer" will be presented in a poster session on Tuesday April 17 from 8:00 am - 12:00 pm. Dr. Missak Haigentz Jr. et al of the Albert Einstein College of M
'"/>

Page: 1 2 3
Related medicine technology :

1. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
2. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
3. Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea